New and investigational antiretroviral drugs for HIV infection: Mechanisms of action and early research findings

Topics in Antiviral Medicine

Volumn 20, Issue 5, 2012, Pages 162-167

  Saag, Michael S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEW DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HIV INFECTIONS; HUMANS;

EID: 84878775158     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Ruane P, DeJesus E, Berger D, et al. GS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300 mg in a 10-day monotherapy study of HIV-1+ patients. [Abstract 103.] 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2012; Washington, DC.
2. Zhou N, Ray N, Healy M, et al. Genotypic and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in a short-term monotherapy study with its prodrug BMS-663068. [Abstract 6.] International Workshop on HIV & Hepatitis Virus Drug Resistance. June 5-9, 2012; Sitges, Spain.
3. Nettles RE, Schurmann D, Zhu L, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 2012;206(7):1002-1011.
4. Gallant J, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as pharmacoenhancers in combination with atazanavir plus tenofovir disoproxil fumarate/ emtricitabine: phase 3 randomized, double blind, active-controlled trial, week 48 results. [Abstract TUAB0103.] 19th International AIDS Conference (IAS). July 22-27, 2012; Washington, DC.
5. Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naive adults: 96-week results from SPRING-1 (ING112276). [Abstract 102LB.] 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2012; Washington, DC.
6. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/ efavirenz: 48-week results-SINGLE (ING114467). [Abstract H-556b.] 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 9-12, 2012; San Francisco, CA.
7. Christ F, Shaw S, Demeulemeester J, et al. Small-molecule inhibitors of the LEDGF/ p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother. 2012;56(8):4365-4374.
8. Benson P, Mayer C, Morales-Ramirez J, et al. Renal safety profile of cobicistat-boosted elvitegravir or atazanavir plus emtricitabine/tenofovir DF in HIV patients. [Abstract H-891.] 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 9-12, 2012; San Francisco, CA.
9. Ward D, Crofoot G, Shamblaw D, et al. Efficacy and safety of elvitegravir/cobicistat/ emtricitabine/tenofovir DF from an integrated analysis of phase 2 and 3 clinical trials. [Abstract H-555.] 52nd Interscience Conference on Antimicrobials and Chemotherapy (ICAAC). September 9-12, 2012. San Francisco, CA.
10. Spreen W, Ford SL, Chen S, et al. Pharmacokinetics, safety and tolerability of the HIV integrase inhibitor s/gsk1265744 long acting parenteral nanosuspension following single dose administration to healthy adults. [Abstract TUPE040.] 19th International AIDS Conference (IAS). July 22-27, 2012; Washington, DC.